Skip to main content
. 2001 Aug;133(8):1213–1218. doi: 10.1038/sj.bjp.0704211

Figure 1.

Figure 1

Effects of the PAR-2 agonist on gastrointestinal transit in mice. The PAR-2 agonist SLIGRL-NH2 (SLp-NH2) or the control peptide LSIGRL-NH2 (LSp-NH2), alone (a) or in combination with i.p. amastatin at 2.5 μmol kg−1 (b), were administered i.p. to the mouse. Data represent the mean±s.e.mean from 4–6 mice. n.s., not significant. Vehicle for amastatin did not modify the gastrointestinal transit.